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preBACKGROUND Secretoneurin (SN) levels are increased in patients with heart failure (HF), but whether SN provides
prognostic information and inﬂuences cardiomyocyte function is unknown.
OBJECTIVES This study sought to evaluate the merit of SN as a cardiovascular biomarker and assess effects of SN on
cardiomyocyte Ca2þ handling.
METHODS We assessed the association between circulating SN levels and mortality in 2 patient cohorts and the
functional properties of SN in experimental models.
RESULTS In 143 patients hospitalized for acute HF, SN levels were closely associated with mortality (n ¼ 66) during
follow-up (median 776 days; hazard ratio [lnSN]: 4.63; 95% conﬁdence interval: 1.93 to 11.11; p ¼ 0.001 in multivariate
analysis). SN reclassiﬁed patients to their correct risk strata on top of other predictors of mortality. In 155 patients with
ventricular arrhythmia–induced cardiac arrest, SN levels were also associated with short-term mortality (n ¼ 51; hazard
ratio [lnSN]: 3.33; 95% conﬁdence interval: 1.83 to 6.05; p < 0.001 in multivariate analysis). Perfusing hearts with SN
yielded markedly increased myocardial levels and SN internalized into cardiomyocytes by endocytosis. Intracellularly, SN
reduced Ca2þ/calmodulin (CaM)-dependent protein kinase II d (CaMKIId) activity via direct SN-CaM and SN-CaMKII
binding and attenuated CaMKIId-dependent phosphorylation of the ryanodine receptor. SN also reduced sarcoplasmic
reticulum Ca2þ leak, augmented sarcoplasmic reticulum Ca2þ content, increased the magnitude and kinetics of cardio-
myocyte Ca2þ transients and contractions, and attenuated Ca2þ sparks and waves in HF cardiomyocytes.
CONCLUSIONS SN provided incremental prognostic information to established risk indices in acute HF and ventricular
arrhythmia–induced cardiac arrest. (J Am Coll Cardiol 2015;65:339–51) © 2015 by the American College of Cardiology
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ABBR EV I A T I ON S
AND ACRONYMS
AUC = area under the receiver-
operating characteristic curve
BNP = B-type
natriuretic peptide
CaM = calmodulin
CaMKIId = Ca2D/calmodulin-
dependent protein kinase II d
CI = conﬁdence interval
COPD = chronic obstructive
pulmonary disease
CV = cardiovascular
CVD = cardiovascular disease
HF = heart failure
HR = hazard ratio
hs-TnT = high-sensitivity
troponin T
ln = natural logarithm
NE = norepinephrine
NT-proBNP = N-terminal pro–
B-type natriuretic peptide
OHCA-VF = out-of-hospital
cardiac arrest with
ventricular ﬁbrillation
PLB = phospholamban
RyR2 = ryanodine receptor 2
SN = secretoneurin
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340C irculating biological substances (bio-markers) can identify speciﬁc patho-physiology in an individual patient
(1). Cardiovascular (CV) biomarkers currently
in clinical use are the B-type natriuretic pep-
tides (BNPs), which reﬂect cardiomyocyte
stress, and cardiac-speciﬁc troponins that
measure cardiomyocyte injury (2). However,
established biomarkers do not assess addi-
tional processes relevant to CV disease (CVD)
progression such as increased neuroendocrine
tone and cardiomyocyte Ca2þ homeostasis.SEE PAGE 352Accumulating evidence suggests that the
chromogranin-secretogranin (granin) family
of proteins plays an important role in cardiac
pathophysiology and may serve as CV bio-
markers (3–8). One interesting member of this
family is the high-capacity, low-afﬁnity Ca2þ-
binding protein secretogranin II (9). Secre-
togranin II is cleaved by the proteases PC1/3
and PC2 to the 33-amino acid peptide secre-
toneurin (SN) (SgII154-186) (9), and these
proteases’ activity is increased by 3-fold in
the failing myocardium (10).
Previous work has shown that SN is the
predominant form of secretogranin II im-munoreactivity in plasma (11,12). By employing an
SN-binding assay (epitope SgII154-165), we have demon-
strated increased circulating SN levels in patientswithheart
failure (HF) (10). Additionally, SN has been shown to
attenuate myocardial ischemia/reperfusion injury, reduce
cardiomyocyte apoptosis, induce angiogenesis, and
improve leftventricular functionaftermyocardial infarction
inexperimental animalmodels (10,13).Given thesedataand
the established role of granin proteins in modulating Ca2þ
handling in noncardiac cells (14), we postulated that SN
couldhaveadirect, protectiveeffect oncardiomyocyteCa2þ
handling.Accordingly, in this studywewanted toassess the
potentialofSNasaprognosticCVbiomarkerandexplorethe
effects of SN on cardiomyocyte Ca2þ homeostasis.
METHODS
Details regarding methods and signiﬁcant statistical
and data elements are found in the Online Appendix.ﬁled by the University of Oslo regarding the use of secretoneu
ith critical illness. All other authors have reported that they have n
.
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t received September 2, 2014; revised manuscript received OctobeCLINICAL COHORTS. We obtained blood samples
<24 h following hospital admission in 143 patients
with acute HF and <6 h following admission in 155
patients with ventricular arrhythmias and out-of-
hospital cardiac arrest (153 patients with ventricular
ﬁbrillation; OHCA-VF). Blood samples were also
available 24 h later in most patients (n ¼ 104 for acute
HF and n ¼ 150 for OHCA-VF) and prior to hospital
discharge in a subset of HF patients (n ¼ 46). We
additionally collected blood samples from 84 patients
with acute chronic obstructive pulmonary disease
(COPD) and from 62 healthy control subjects. Survival
status was obtained from electronic hospital records.
EXPERIMENTAL MODELS. Internalization of SN
(2.8 mM and 28 nM) was studied in neonatal mouse
and rat cardiomyocytes and in isolated mouse hearts.
For assessment of phosphorylation status, BayK
(10 mM) was included in the perfusate of mouse hearts
ex vivo to enhance myocardial Ca2þ/calmodulin
(CaM)-dependent protein kinase II d (CaMKIId) ac-
tivity. Immunoblotting was performed with a primary
antibody for SN (SgII172-186) (15). We assessed
SN-CaMKIId and SN-CaM interactions by several
methods, and examined CaMKIId activity in vitro by
kinase activity assays. The effects of SN treatment on
cardiomyocyte Ca2þ homeostasis were examined in
isolated ventricular myocytes from adult healthy
mice and in ventricular myocytes obtained adjacent
to the infarct area (border zone) in HF rats (Online
Table 1, Online Figure 1).
STATISTICAL ANALYSIS. Clinical data are expressed
as mean  SD with the exception of biomarkers,
which are reported as median (quartile 1 to 3), and
experimental data are presented as mean  SEM.
Differences between groups were examined by the
Student t test or the Mann-Whitney U test, and serial
measurements tested by the related-samples Wil-
coxon signed rank test. Categorical data are presented
as absolute numbers and percents, and were
compared by the chi-square or the Fisher Exact test.
We used Spearman rank correlation, and de-
terminants of biomarker levels were assessed by
linear regression analyses. Prognostic utility was
assessed by Kaplan-Meier plots with SN quartiles
compared by the log-rank test and by Coxrin as a biomarker in cardiovascular disease and in
o relationships relevant to the contents of this paper
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FIGURE 1 SN Presence in HF Patients as Assessed by Liquid Chromatography-Mass
Spectrometry
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Secretoneurin, Theoretical Mass Spectrum for [M - 3h]3-A
B
C
The mass spectrum of secretoneurin (SN) based on (A) theoretical calculation and the mass
spectrum of (B) synthetic SN and (C) SN in heart failure (HF) patient samples were nearly
identical.
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341proportional hazards regression analysis. Biomarkers
were transformed by the natural logarithm (ln) before
regression analyses. Calibration of the basic risk
model was examined by calculating the category-free
net reclassiﬁcation index (16), and prognostic accu-
racy was assessed by calculating the area under
the receiver-operating characteristic curve (AUC);
p values <0.05 were considered signiﬁcant.
The clinical studies were approved by the Regional
Ethics Committees and the experimental studies
performed according to National Institutes of Health
guidelines.
RESULTS
CIRCULATING SN LEVELS ON ADMISSION IN
PATIENTS WITH ACUTE HF. We ﬁrst conﬁrmed the
presence of free SN in the circulation of HF patients
by liquid chromatography-mass spectrometry. The
mass spectra of SN based on theoretical calculation
(Figure 1A) and synthetic SN (Figure 1B) were found to
be nearly identical to the spectrum in the plasma of
HF patients (Figure 1C).
Using radioimmunoassay (17), we measured SN
levels of 140 (122 to 170) pmol/l in acute HF patients
with a range between 84 and 677 pmol/l (Figure 2A). SN
levels correlated with N-terminal pro–B-type natri-
uretic peptide (NT-proBNP) (r ¼ 0.38; p < 0.001) and
high-sensitivity troponin T (hs-TnT) levels (r ¼ 0.27;
p ¼ 0.001), but not with left ventricular ejection frac-
tion (r ¼ –0.03; p ¼ 0.77) or norepinephrine (NE) levels
(r ¼ 0.15; p ¼ 0.08). Patients classiﬁed as New York
Heart Association functional class IV exhibited higher
SN levels than the other patients (Online Figure 2).
Creatinine clearance, diabetes mellitus, age, inhala-
tion therapy with short-acting b2-agonist, and NT-
proBNP levels were associated with SN levels (details
in Online Appendix). The duration of dyspnea prior to
hospital admission (Online Figure 3) and the time from
hospital admission to blood sampling did not inﬂuence
SN levels in the acute HF patients (r ¼ –0.06; p ¼ 0.46).
ADMISSION SN LEVELS ASSOCIATED WITH
MORTALITY IN PATIENTS WITH ACUTE HF. Sixty-six
patients (46%) died during a median follow-up of
776 (246 to 983) days (patient characteristics accord-
ing to mortality in Online Table 2). There was a
graded increase in mortality in proportion to
admission SN levels (Central Illustration) (p < 0.001).
SN was strongly associated with mortality by Cox
regression analyses that adjusted for other risk var-
iables, including NT-proBNP, hs-TnT, and NE levels
(hazard ratio [HR] [lnSN]: 4.63; 95% conﬁdence in-
terval [CI]: 1.93 to 11.11; p ¼ 0.001) (Table 1 and
Online Table 3 with medication). Adding SN to a
FIGURE 2 SN Levels and Mortality
225
200
175
150
125
100
75
0
100
80
60
40
20
0
0 5 10 15 20 25 30
SN
 (p
m
ol
/L
)
p=0.01
p<0.001
p<0.001
Acute HF
OHCA-VF
Healthy subjects
Baseline After 24 h
Su
rv
iv
al
 P
ro
ba
bi
lit
y 
(%
)
Follow-up (Days)
OHCA-VF
SN levels
Q1
Q2
Q3
Q4
A
B
(A) In acute HF and out-of-hospital cardiac arrest with ventricular ﬁbrillation (OHCA-VF)
patients, secretoneurin (SN) levels were higher than in healthy subjects, with the highest
level observed in OHCA-VF. After 24 h hospitalization, levels declined in OHCA-VF
(p < 0.001) but remained elevated in acute heart failure (HF) patients. The horizontal line
within the box represents the median concentration and the boundaries of the box quar-
tiles (Q) 1 to 3. (B) Patients stratiﬁed according to SN quartiles on hospital admission in
OHCA-VF (n ¼ 155; p < 0.001 by the log-rank test).
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342model of clinical variables independently associated
with mortality in our dataset, including NT-proBNP
levels, reclassiﬁed a signiﬁcant proportion of the pa-
tients to their correct risk strata (net reclassiﬁcationindex ¼ 41%; p ¼ 0.01). The effect by SN was primarily
to lower the risk score in 69% of HF survivors (Online
Figure 4A). SN discriminated between patients with a
poor and a favorable prognosis in acute HF (AUC¼ 0.71
[95%CI: 0.63 to 0.78]); AUCswere lower for NT-proBNP
(0.67 [95% CI: 0.59 to 0.75]) and hs-TnT levels (0.65
[95% CI: 0.57 to 0.73]).
Circulating SN levels measured on admission for
acute COPD were lower than admission levels in acute
HF (median 136 [117 to 145] pmol/l; p ¼ 0.025 vs. acute
HF) and did not provide prognostic information for
all-cause mortality (Online Figure 5). Of note, mor-
tality rates and dyspnea severity were comparable
between patients with acute COPD and acute HF
(Online Table 4).
VENTRICULAR ARRHYTHMIA–INDUCED CARDIAC
ARREST. SN levels provided prognostic information
in acute HF but not acute COPD. As ventricular ar-
rhythmias frequently are the immediate cause of
death in HF patients, we also measured SN levels in
an additional cohort of 155 patients with ventricular
arrhythmia–induced cardiac arrest. In this cohort,
median (quartile 1 to 3) SN level was 158 (122 to 209)
pmol/l with values ranging from 58 to 2150 pmol/l
(Figure 2A). SN levels correlated with time to return of
spontaneous circulation (r ¼ 0.27; p ¼ 0.001) and
estimated creatinine clearance (r ¼ –0.35; p < 0.001),
but not with cardiac biomarkers. Creatinine clear-
ance, diabetes mellitus, and age were associated with
SN levels after OHCA-VF.
In 62 healthy control subjects (38 male [61%], me-
dian age 58 [51 to 68] years), the median SN level was
121 (103 to 141) pmol/l (Figure 2A), which was lower
than SN levels on admission for acute HF and OHCA-
VF (p < 0.001 for both). Fifty-one patients (32%)
hospitalized after successful resuscitation for OHCA-
VF died within 30 days (characteristics according to
mortality status in Online Table 5). Patients with SN
levels in the fourth quartile had worse prognosis than
patients with lower SN levels (Figure 2B) (p < 0.001).
SN levels were also associated with short-term mor-
tality in patients with OHCA-VF after adjusting for
other risk factors (HR [lnSN]: 3.33; 95% CI: 1.83 to
6.05): p < 0.001) (Table 2).
SERIAL SN LEVELS DURING HOSPITALIZATION FOR
ACUTE HF AND OHCA-VF. Circulating SN levels in
the ﬁrst blood sample after admission for OHCA-VF
were higher than baseline SN levels in acute HF pa-
tients (p ¼ 0.01) (Figure 2A). However, although SN
levels in OHCA-VF patients declined during the ﬁrst
24 h (p < 0.001) (Figure 2A), no changes were
observed during day 1 in the acute HF patients.
Accordingly, SN levels were higher after 24 h in HF
CENTRAL ILLUSTRATION Secretoneurin: Calcium Regulator and Biomarker
(A) As a biomarker, secretoneurin (SN) levels stratify mortality risk at hospital admission for patients with acute heart failure (p < 0.001 by the log-rank test for SN
quartiles [Q]). (B) Experimental studies of SN in isolated cells and explanted hearts demonstrate that (1.) SN is internalized into cardiomyocytes and the intact heart by
endocytosis. (2.) SN binds directly to calmodulin (CaM) and CaM-dependent protein kinase II d (CaMKIId), and inhibits CaMKIId activity. (3.) This leads to reduced
Ser2814-ryanodine receptor 2 (RyR2) phosphorylation, and (4.) improved Ca2þ homeostasis.
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343patients than in patients successfully resuscitated for
OHCA-VF (p < 0.001) (Figure 2A).
In the subset of HF patients with serial biomarker
measurements, the AUC for all-cause mortality for SN
levels measured after 24 h was 0.65 (95% CI: 0.55 to
0.74) compared to 0.63 (95% CI: 0.53 to 0.72) for NT-
proBNP, although the AUC on discharge for SN was
0.61 (95% CI: 0.45 to 0.74) and 0.56 (95% CI: 0.41 to
0.71) for NT-proBNP. Compared to concentrations at
baseline, NT-proBNP levels tended to be lower after
24 h (median reduction 117 pg/ml; p ¼ 0.065) and
were signiﬁcantly reduced at hospital discharge
(median reduction 1172 pg/ml; p < 0.001). NE levels
also were signiﬁcantly reduced prior to hospital
discharge (median reduction 1,596 pmol/l; p ¼ 0.001).
In contrast, SN levels stayed unchanged during the
HF hospitalization with median 1.0 pmol/l increase
during the ﬁrst 24 h (p ¼ 0.91) and median 1.0 pmol/l
decrease on discharge (p ¼ 0.37).
SN INTERNALIZED INTO CARDIOMYOCYTES AND
THE INTACT HEART. On the basis of the strongassociation between SN levels and mortality in CVD
and the association between granin proteins and Ca2þ
homeostasis in noncardiac cells (14), we examined
whether SN affects cardiomyocyte Ca2þ homeostasis.
Although the receptor for SN has not been identiﬁed
(9), a report has suggested that other short granin-
derived peptides are internalized in cells by endocy-
tosis (18), so we examined whether SN may be
directly internalized into isolated cardiomyocytes
and into the intact heart. We observed increased
intracellular cardiomyocyte SN levels in proportion to
the SN concentration in the suspension (Figure 3A).
The internalization of SN was validated by confocal
ﬂuorescence microscopy (Figure 3B, Online Video 1).
SN colocalized with Alexa 647–labeled transferrin
(Invitrogen/Molecular Probes, Carlsbad, California)
(Figure 3B), which is internalized via clathrin-
mediated endocytosis (19) but not with dextran-
alexa647, a marker of unspeciﬁc macropinocytosis
(Online Video 1). SN also colocalized with markers of
early (EEA1) and late endosomes (LAMP1) (Figure 3C).
TABLE 1 Predictors of Mortality During Follow-Up in Patients With Acute
Heart Failure
Hazard Ratio 95% CI p Value
Univariate analysis
Age, per 1-yr increase 1.04 1.02–1.07 0.002
Male 0.53 0.32–0.86 0.010
Body mass index, per 1 unit increase 0.94 0.89–0.99 0.012
Creatinine clearance, ml/min 0.98 0.97–0.99 <0.001
Heart rate, admission 1.00 0.99–1.01 0.40
Systolic blood pressure, admission, mm Hg 0.99 0.98–0.99 0.004
Diastolic blood pressure, admission, mm Hg 0.97 0.96–0.99 0.001
NYHA functional class IV versus II/III 2.01 1.23–3.29 0.006
LVEF, continuous 1.00 0.98–1.02 0.88
History of
Heart failure 1.43 0.86–2.38 0.17
Myocardial infarction 1.00 0.62–1.63 1.00
PCI 0.69 0.37–1.29 0.24
CABG 1.17 0.66–2.05 0.59
Hypertension 0.83 0.51–1.36 0.47
Atrial ﬁbrillation 1.07 0.66–1.74 0.78
Diabetes mellitus 1.78 1.08–2.95 0.024
Chronic obstructive pulmonary disease 1.85 1.14–3.01 0.013
lnSN, admission* 5.06 2.83–9.03 <0.001
lnNT-proBNP, admission* 1.53 1.24–1.89 <0.001
lnhs-TnT, admission* 1.37 1.10–1.71 0.005
lnNE, admission* 2.40 1.33–4.32 0.004
Multivariate analysis: ﬁnal model
Age, per 1-yr increase 1.06 1.03–1.09 <0.001
Systolic blood pressure, admission, mm Hg 0.99 0.98–0.99 0.001
Diabetes mellitus 1.77 1.02–3.09 0.044
Chronic obstructive pulmonary disease 2.20 1.29–3.76 0.001
lnSN, admission* 4.63 1.93–11.11 0.001
lnNT-proBNP, admission* 1.44 1.12–1.85 0.005
lnNE, admission* 2.01 1.06–3.82 0.033
*Transformed by the natural logarithm (ln) before regression analysis.
CABG ¼ coronary artery bypass grafting; CI ¼ conﬁdence interval; hs-TnT ¼ high-sensitivity
cardiac troponin T; LVEF ¼ left ventricular ejection fraction; NE ¼ norepinephrine; NT-
proBNP ¼ N-terminal pro–B-type naturietic peptide; NYHA ¼ New York Heart Association;
PCI ¼ percutaneous coronary intervention; SN ¼ secretoneurin.
TABLE 2 Predictors of Short-Term Mortality in Patients With
Ventricular Arrhythmia–Induced Cardiac Arrest
Hazard Ratio 95 % CI p Value
Univariate analysis
Age, per 1-yr increase 1.04 1.01–1.06 0.005
Male 1.33 0.57–3.13 0.51
Body mass index, per 1-U
increase
1.02 0.96–1.08 0.59
Creatinine clearance, ml/min 0.99 0.98–0.99 0.025
History of
Coronary artery disease 2.11 1.22–3.67 0.008
Diabetes mellitus 1.76 0.97–3.22 0.065
Hypertension 1.50 0.86–2.60 0.15
Heart failure 2.38 1.27–4.48 0.007
Witnessed cardiac arrest 0.32 0.15–0.69 0.004
Bystander CPR 0.90 0.51–1.60 0.72
Time to ROSC 1.05 1.03–1.07 <0.001
Therapeutic hypothermia 0.93 0.42–2.06 0.86
Coronary angiography 0.33 0.13–0.82 0.018
PCI 0.15 0.02–1.11 0.064
lnSN, admission* 1.92 1.25–2.95 0.003
lnNT-proBNP, admission* 1.39 1.12–1.73 0.003
lnhs-TnT, admission* 1.25 1.02–1.55 0.034
Multivariate analysis: ﬁnal model
Age, per 1-yr increase 1.06 1.03–1.09 <0.001
Witnessed cardiac arrest 0.31 0.14–0.66 0.003
Time to ROSC 1.05 1.03–1.08 <0.001
lnSN levels, admission* 3.33 1.83–6.05 <0.001
*Transformed by the natural logarithm before regression analysis.
CPR ¼ cardiopulmonary resuscitation; ROSC ¼ return of spontaneous circula-
tion; other abbreviations as in Table 1.
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344We also observed a diffuse cytosolic SN signal that
may reﬂect release of SN from endosomes. SN accu-
mulated in the myocardium of isolated hearts
perfused with SN (2.8 mM) (Figure 3D), indicating that
SN internalization also occurs in the intact organ.
SN INHIBITS CAMKIId VIA DIRECT SN-CALMODULIN
AND SN-CAMKIId INTERACTIONS. Bioinformatic
analyses suggested that SN binds directly to both
CaMKII and CaM (Figures 4A and 4B), which are nodal
kinases that regulate intracellular Ca2þ handling in
cardiomyocytes (20). In line with this, SN coprecipi-
tated with CaMKIId in HEK293 cells overexpressing
His-CaMKIId-T287D (Figure 4C). We also found a Ca2þ-
dependent direct interaction between recombinant
His-CaMKIId-T287D and SN by immunoprecipitation
(Figure 4D) as well as a direct interaction betweenendogenous CaMKIId and SN in intact hearts perfused
with SN (Online Figure 6A). A direct interaction be-
tween SN and CaMKIId was further demonstrated by
surface plasmon resonance analyses, which revealed
a dissociation equilibrium constant (KD) for SN-CaM-
KIId of 8  3  10–8 M, an association rate constant (ka)
of 3  1  103 M–1s–1, and a dissociation rate constant
(kd) of (3  2)  10–4 s–1 (Figure 4E). This interaction
was not present in the absence of Ca2þ. We further
observed SN to bind CaM in a CaM-agarose pull-down
experiment in the presence of Ca2þ. Precipitation was
markedly attenuated in the presence of ethylene
glycol tetraacetic acid, supporting a Ca2þ-dependence
of the SN-CaM interaction (Figure 4F). Consistent with
literature reports and validating the experimental
conditions, CaM-agarose also precipitated CaMKIId
in a Ca2þ-dependent fashion (Online Figure 6B).
There was a direct SN-CaM interaction by surface
plasmon resonance analyses with a KD of 1.4  0.3 
10–7 M, a ka of 1.3  0.1  103 M–1s–1, and a kd ¼ 1.8 
0.2  10–4 s–1 (Figure 4G).
Using an in vitro kinase assay we observed that
SN reduced CaMKIId activity in a dose-dependent
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345manner (Figure 4H). Although SN showed some
sequence similarity to the region containing
the Thr286 autophosphorylation site in CaMKII
(Online Figure 6C), no phosphorylation of SN was
observed (Online Figure 6D). We found no chelating
effect of SN on Ca2þ (Online Figure 6E); thus, inhibi-
tion of CaMKIId activity by SN cannot be attributed to
direct Ca2þ buffering.
SN REDUCES CAMKIId PHOSPHORYLATION. Auto-
phosphorylation of CaMKIId at Thr286 leads to acti-
vation of the catalytic domain and a constitutively
active kinase (21). Treating isolated cardiomyocytes
with SN (2.8 mM) reduced CaMKIId autophosphor-
ylation compared to control cells (Figure 5A). Simi-
larly, in isolated mouse hearts perfused with BayK,
inclusion of SN (2.8 mM) in the perfusate reduced
myocardial CaMKIId autophosphorylation (Figure 5B).
The ryanodine receptor 2 (RyR2) is the major
intracellular Ca2þ release channel in cardiomyocytes
and its function is closely regulated by CaMKIId
phosphorylation (20). We assessed RyR2 phosphory-
lation at Ser2814, an established CaMKIId regulatory
site (20), in isolated BayK-perfused mice hearts in
the presence and absence of SN. We observed a
prominent BayK-induced increment in Ser2814-RyR2
phosphorylation, which was reversed by adding SN to
the perfusate (Figure 5C). In contrast, Ser2808-RyR2
phosphorylation (Figure 5D), which is regulated by
protein kinase A (22), was not inﬂuenced by BayK or
SN treatment (Figure 5D).
We examined whether SN affects phosphorylation
of phospholamban (PLB), a kinase that controls Ca2þ
reuptake into the sarcoplasmic reticulum via the
sarcoplasmic reticulum Ca2þ transport ATPase (20).
Similar to observations made for RyR2, SN reduced
CaMKIId-dependent phosphorylation of Thr17-PLB
(Figure 5E), but did not inﬂuence protein kinase A-
regulated Ser16-PLB phosphorylation (Figure 5F).
SN MODULATES CARDIOMYOCYTE CALCIUM HOMEOSTASIS.
As SN regulates CaMKIId-dependent phosphorylation
of RyR2 and PLB, we assessed SN effects on car-
diomyocyte Ca2þ handling. In line with reduced
CaMKIId activity at RyR2, SN (2.8 mM) reduced Ca2þ
spark frequency in permeabilized and intact car-
diomyocytes (Figure 6A). Using a 100-fold lower SN
concentration (28 nM), which is only w10-fold higher
than circulating levels in patients and within the
presumed myocardial SN concentration range after
taking into account para- and autocrine production,
SN induced a consistent and marked reduction in
Ca2þ spark frequency (Figure 6A). SN treatment also
reduced incidence of both Ca2þ sparks and waves in
cardiomyocytes isolated from rats exhibiting HF
following myocardial infarction (Figure 6B). SNtreatment increased themagnitude of caffeine-elicited
Ca2þ release, but did not affect rates of sarcoplasmic
reticulum Ca2þ reuptake or sarcolemmal extrusion of
Ca2þ (Figure 6C), thus linking the SN-induced incre-
ment in sarcoplasmic reticulum Ca2þ content to a
reduction in RyR2 Ca2þ leak. Additionally, SN en-
hanced cardiomyocyte Ca2þ transient amplitude and
reduced the time to half decay of the transient
(Figure 6D), increased cardiomyocyte contraction
amplitude, and reduced the time to peak of the
contraction (Figure 6E).
DISCUSSION
This study’s principal results show that circulating
SN levels provide strong prognostic information in
patients with CVD and SN inﬂuences cardiomyocyte
Ca2þ handling via direct CaMKIId inhibition (Central
Illustration). Accordingly, SN seems to be a novel
protective mediator activated in the most severely
ill HF patients and a biomarker that reﬂects CV
pathophysiology not covered by established risk
indices.
A key requirement of novel biomarkers is that they
add information beyond what is already available
through established indices. In the present study, we
demonstrate that SN provides incremental informa-
tion to patient history, clinical assessment, and levels
of hs-TnT, NT-proBNP, and NE in independent co-
horts of patients with CVD. We chose to validate our
results in a large cohort of OHCA-VF patients, as
ventricular arrhythmias are responsible for a sizable
proportion of HF deaths. The high SN levels measured
within 6 h of OHCA-VF indicate patients with ven-
tricular arrhythmias will have high circulating SN
levels; those with more severe damage will have the
highest levels. Of note, SN levels in healthy subjects
were markedly lower than those in patients hospi-
talized for acute HF or after ventricular arrhythmia–
induced cardiac arrest.
Accordingly, 3 SN characteristics seem to explain
the powerful effect by SN on CV risk assessment:
1) circulating SN levels appear more narrowly distrib-
uted than most other circulating protein biomarkers
(as found in the healthy subjects); 2) SN levels are
strongly increased in the subgroup of patients with
high risk of subsequent mortality; and 3) there are no
close correlations between SN levels and other indices
of risk, including hs-TnT, NT-proBNP, and NE levels.
The relative contribution by different organs to
circulating SN levels in CVD has not been fully
established. However, current data support SN
release to the circulation from the neuroendocrine
system and from damaged cardiomyocytes and
FIGURE 3 SN Internalized Into Cardiomyocytes and the Intact Heart
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FIGURE 4 SN: Endogenous CaMKIId Inhibitor Via Direct SN-CaM and SN-CaMKII Binding
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FIGURE 5 SN Reduced CaMKIId Autophosphorylation and CaMKIId-Dependent Phosphorylation of RyR2 and PLB
120
100
80
60
40
20
0
Re
la
tiv
e 
pT
hr
28
6-
Ca
M
KI
I
Le
ve
l (
%
)
Ctr
SN
Ctr
SN
*
*
*
anti-pCaMKII
anti-CaMKIIδ
anti-pCaMKII
anti-CaMKIIδ
Ctr CtrSN
50
50
560 9
9
9
560
560
50
50
BayK SN + BayK
Ct
r
Ba
yK
SN
+B
ay
K
Ctr
BayK
SN + BayK
Ctr
BayK
SN + BayK
anti-pSer2814-RyR2
anti-pSer2808-RyR2
anti-RyR2
ISO
Ctr SNISO
anti-pThr-PLB
anti-pSer16-PLB
anti-PLB
160
140
120
100
80
60
40
20
0R
el
at
iv
e 
pT
hr
28
6-
Ca
M
KI
I
Le
ve
l (
%
)
***
225
200
175
125
150
100
75
50
25
0
Re
la
tiv
e 
pS
er
28
14
-R
yR
2
Le
ve
l (
%
)
225
200
175
125
150
100
75
50
25
0
100
400
600
800
1000
50
0R
el
at
iv
e 
pS
er
28
08
-R
yR
2
Le
ve
l (
%
)
200
300
400
100
50
0
Re
la
tiv
e 
pS
er
16
-P
LB
Le
ve
l (
%
)
Re
la
tiv
e 
pT
hr
17
-P
LB
Le
ve
l (
%
)
A
C D E F
B
(A) Secretoneurin (SN) reduced autophosphorylation of Thr286-CaMKII in isolated neonatal cardiomyocytes. (B) SN reduced myocardial Thr286-CaMKII autophos-
phorylation in BayK-perfused hearts. (C,D) SN reduced myocardial BayK-induced Ser2814-RyR2 phosphorylation, but not Ser2808-RyR2 phosphorylation. (E,F) SN
reduced CaMKII-dependent phosphorylation of Thr17-PLB in isolated neonatal cardiomyocytes, but demonstrated no effect on Ser16-PLB. ISO (100 nM) was used as a
positive control. The lower panels are representative immunoblots. *p < 0.05; **p < 0.01. CaMKII ¼ calmodulin-dependent protein kinase II d; PLB ¼ phospholamban;
RyR2 ¼ ryanodine receptor 2.
Ottesen et al. J A C C V O L . 6 5 , N O . 4 , 2 0 1 5
Secretoneurin, Biomarker, and Calcium Regulation F E B R U A R Y 3 , 2 0 1 5 : 3 3 9 – 5 1
348myocardium on the basis of increased SN immuno-
reactivity in the myocardium, but not in other organs
(e.g., liver, spleen) of post-infarction HF mice (10).
Neuroendocrine cells likely also contribute to circu-
lating SN levels as granin proteins are found
throughout the neuroendocrine system (9). SN levels
were high within 6 h of OHCA-VF and normalized
after cardioversion, which might support the release
of SN from injured cardiomyocytes in situations of
profound systemic and myocardial stress. Further-
more, as SN levels returned to normal within 24 h, SN
seems to be a dynamic CV biomarker that reﬂects
clinical outcome.Additional support for the theory that SN is a
biomarker speciﬁc for CVD is derived from the
observed correlations between SN levels and levels
of hs-TnT and NT-proBNP on admission for acute
HF, and from the lack of prognostic value of SN
levels in acute COPD. SN appears to be regulated by
different mechanisms than established CV bio-
markers, as elevated SN levels were observed
throughout the acute HF admission, whereas NT-
proBNP and NE levels decreased during hospitaliza-
tion. Thus, SN provided a consistent and strong
signal of pathophysiology of relevance for survival
that was not modiﬁed by our HF patients’ current
FIGURE 6 SN Modulates Cardiomyocyte Calcium Homeostasis
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350therapy. Determination of the precise stimuli for SN
production in HF will require additional study, but
previous data have found that hypoxia, NE, and
transforming growth factor-b stimulation increase
SN production in cardiomyocytes (10,13). In contrast,
as in our work here, previous data (23) also suggest
that SN is not a surrogate marker for NE levels, nor a
marker that is correlated with left ventricular ejec-
tion fraction. SN levels were higher in patients with
impaired renal function, probably as a result of
reduced clearance.
Earlier work has demonstrated beneﬁcial effects of
SN, including in vivo effects following myocardial
infarction (13), but no direct receptor for SN has been
identiﬁed (9,13). We now propose endocytosis,
intracellular vesicle transport, and the release of SN
into the cytosol as an alternative mechanism whereby
SN may regulate cellular function. Endocytosis rep-
resents a mechanism permitting internalization of
substances from interstitial ﬂuid or plasma to distinct
intracellular compartments (24). Internalization by
endocytosis has also been reported for chromogranin
A–derived peptides (18), suggesting that endocytosis
could be an important mechanism whereby short
granin peptides modulate cellular function.
We also present novel data that SN modiﬁes car-
diomyocyte Ca2þ handling by reducing CaMKIId ac-
tivity via a direct interaction. Our data on the effects
of SN on cardiomyocyte Ca2þ homeostasis support the
theory that SN acts as a CaMKIId inhibitor, which has
been found to reduce Ca2þ sparks while increasing
sarcoplasmic reticulum Ca2þ content and the magni-
tude of Ca2þ transients and contractions (25,26).
Whether SN may also reduce CaMKII activity due to
increased oxidant stress (27) will require additional
study. However, we demonstrate that SN reduces the
frequency of Ca2þ sparks and waves in HF car-
diomyocytes obtained from the border zone of the
infarcted left ventricle, the area with the most pro-
nounced oxidative stress (27).
Substances that are increased in the circulation of
HF patients in proportion to disease severity may
both promote disease progression or represent pro-
tective compensatory mechanisms. The observed ac-
tions of SN on cardiomyocyte Ca2þ homeostasis
would be expected to be protective. Spontaneous RyR
openings and resulting delayed afterdepolarizations
are established mechanisms underlying triggered
arrhythmia; excessive CaMKII-dependent sensitiza-
tion of RyRs to Ca2þ is believed to contribute to
increased arrhythmogenesis (20) and CaMKII inhibi-
tion protects against triggered arrhythmia (25).
Hence, SN may be a compensatory mechanism during
ventricular arrhythmias, a theory supported by theﬁndings of high SN levels within 6 h of ventricular
arrhythmia–induced cardiac arrest. HF is also widely
reported to be associated with reduced sarcoplasmic
reticulum Ca2þ content and release (28) and the larger
Ca2þ transients and contractions observed during SN
would be expected to counteract such deﬁcits.
Accordingly, SN is released by neuroendocrine and
myocardial cells and reﬂects clinical outcome in CVD,
whereas the direct effects of SN on CV pathophysi-
ology may be protective by reducing diastolic Ca2þ
leak via direct CaMKIId inhibition. This is analogous
to high BNP levels being associated with poor prog-
nosis, whereas the physiological effects of BNP are
considered protective in CVD (2). The association
between SN levels and cardiomyocyte Ca2þ homeo-
stasis also may explain the potent prognostic infor-
mation provided by SN in acute HF but not acute
COPD, although we do not have access to cause of
death in the HF patients. Alternatively, SN release
from injured cardiomyocytes could have a local,
negative effect via augmented CaMKIId activity and
increased spontaneous Ca2þ release.
STUDY LIMITATIONS. The lack of information on the
cause of death in our HF patients is a limitation of our
study.
CONCLUSIONS
Circulating SN levels provide strong and comple-
mentary information to established risk indices in
patients with acute HF and in patients with ventric-
ular arrhythmia–induced cardiac arrest. We also
demonstrated a direct effect by SN on cardiomyocyte
Ca2þ handling via inhibition of CaMKIId activity, a key
pathophysiological mediator in CVD.
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PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE:
Cardiovascular biomarkers such as B-type natriuretic pep-
tides, which reﬂect cardiomyocyte stress, and cardiac-
speciﬁc troponins, which reﬂect cardiomyocyte injury have
diagnostic and prognostic value and are useful in guiding
clinical management. Additional substances, such as secre-
toneurin (SN) may provide additional, complementary in-
formation proportionate to cardiovascular disease severity.
TRANSLATIONAL OUTLOOK: Additional clinical
studies are needed to validate the incremental diagnostic
value and therapeutic implications of novel biomarkers
such as SN that reﬂect cardiomyocyte membrane
permeability and may correlate with risk of progressive
heart failure and ventricular arrhythmias.
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APPENDIX For expanded Methods,
Results, and References sections, and supple-
mental tables, ﬁgures, and a video, please see
the online version of this article.
